Three different topics below... 1.)"Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients": The White House February 5, 2026 https://trumprx.gov/ https://www.whitehouse.gov/fact-sheets/2026/02/fact-sheet-president-donald-j-trump-launches-trumprx-gov-to-bring-lower-drug-prices-to-american-patients/ 2.) "Regulatory Pathway Analysis for FDA Approval of Mushroom-Based Supplements": February 3, 2026 https://shroomfan.com/health-wellness/regulatory-pathway-analysis-for-fda-approval-of-mushroom-based-supplements/ 3.) What is the FDA's "latest" policy regarding "expediting" drug development?... "In September, I met with FDA Director Dr. Marty Makary to discuss the agency's latest policies towards expediting drug development by safely removing unnecessary red tape." https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177239821 The latest policy regarding expediting drug development is also the only approval acceleration option that directly involves meeting with the Commissioner...maybe we should have a betting pool for which acceleration option they will go with... "Commissioner's National Priority Voucher (CNPV) Pilot Program": https://www.fda.gov/industry/commissioners-national-priority-voucher-cnpv-pilot-program The others can all be enacted by CDER without the Commissioner being directly involved... "Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review": https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review
Market Data 
Markets
AI
